semaglutide and cardiovascular outcomes in obesity Long-term weight loss effects of without diabetes in the SELECT trial Association between semaglutide 2.4 mg

CrossRef Clinical differentiation between alcohol-associated and metabolic dysfunction-associated steatotic liver disease: a comparative case report Chang-Gue Son The Journal of Internal Korean Medicine .2026

Two GLP-1s (Saxenda and Wegovy) are currently approved for use in adolescents ages 12 and up

It also explained why two people's blood was not always compatible with one another

Potential benefits are not guaranteed

Remember: GLP-1 drugs like semaglutide and tirzepatide can be safe and effective tools when used responsibly, but only under proper medical supervision

A 2025 joint advisory published in the American Journal of Clinical Nutrition and narrative reviews recommend GLP-1 users consume 1.21.6 grams of protein per kilogram of body weight daily, with intake distributed evenly across meals